An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

Immunity and Ageing

Volumn 9, Issue , 2012, Pages

  Cherukuri, Anu ^a   Stokes, Kate L ^b,c   Patton, Kathryn ^a   Kuo, Howard ^a   Sakamoto, Kaori ^d   Lambert, Stacie ^a   Stillman, Elizabeth ^a   Moore, Martin L ^b,c   Lee, Sujin ^b,c  

^a MEDIMMUNE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adjuvant; Aged mice; Alum; Immunosenescence; Respiratory Syncytial Virus

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CXCL1 CHEMOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS F PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; EOSINOPHIL; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; LUNG EDEMA; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; TH2 CELL; VACCINATION; VIRUS LOAD; WILD TYPE;

EID: 84866782608     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-9-21     Document Type: Article

References (27)

1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352(17):1749-1759. 10.1056/NEJMoa043951, 15858184.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140(6):543-546.
3. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 2005, 22(7):577-587. 10.2165/00002512-200522070-00004, 16038573.
4. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008, 7(2):249-258. 10.1586/14760584.7.2.249, 18324893.
5. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239(1):149-166. 10.1111/j.1600-065X.2010.00972.x, 3023887, 21198670.
6. Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, Graham BS. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997, 15(5):525-532. 10.1016/S0264-410X(97)00218-1, 9160520.
7. Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J Infect Dis 1994, 170(2):425-428. 10.1093/infdis/170.2.425, 8035030.
8. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15(10):1130-1132. 10.1016/S0264-410X(97)00002-9, 9269057.
9. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996, 14(13):1214-1218. 10.1016/S0264-410X(96)00030-8, 8961507.
10. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009, 29(4):725-739. 10.1016/j.cll.2009.07.004, 2774466, 19892231.
11. Empey KM, Peebles RS, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50(9):1258-1267. 10.1086/651603, 2851489, 20235830.
12. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8(5):497-502. 10.1016/0264-410X(90)90253-I, 2251875.
13. Vaux-Peretz F, Chapsal JM, Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine 1992, 10(2):113-118. 10.1016/0264-410X(92)90027-H, 1539464.
14. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines-US perspective. Vaccine 2002, 20(Suppl 3):S18-S23.
15. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008, 198(9):1317-1326. 10.1086/592168, 18855558.
16. Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine 2009, 27(42):5913-5919. 10.1016/j.vaccine.2009.07.038, 19651171.
17. Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM. Respiratory syncytial virus infection in inbred mice. Infect Immun 1979, 26(2):764-766. 414679, 546793.
18. Hancock GE, Hahn DJ, Speelman DJ, Hildreth SW, Pillai S, McQueen K. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine 1994, 12(3):267-274. 10.1016/0264-410X(94)90204-6, 8165859.
19. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991, 88(3):1026-1033. 10.1172/JCI115362, 295511, 1909350.
20. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7(12):1374-1386. 10.4161/hv.7.12.18322, 3338934, 22048171.
21. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995, 182(4):1169-1174. 10.1084/jem.182.4.1169, 2192289, 7561691.
22. Kariyawasam HH, Robinson DS. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 2006, 27(2):117-127. 10.1055/s-2006-939514, 16612762.
23. Zhang Y, Wang Y, Gilmore X, Xu K, Wyde PR, Mbawuike IN. An aged mouse model for RSV infection and diminished CD8(+) CTL responses. Exp Biol Med (Maywood) 2002, 227(2):133-140.
24. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17(8):996-1002. 10.1038/nm.2403, 21765404.
25. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(4):479-487. 10.1038/nm.2306, 21399646.
26. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Goleniewska K, et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 2009, 83(9):4185-4194. 10.1128/JVI.01853-08, 2668460, 19211758.
27. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011, 85(12):5782-5793. 10.1128/JVI.01693-10, 3126300, 21471228.